Enzyme Replacement Therapy in Late-Onset Pompe's Disease: A Three-Year Follow-up

Annals of Neurology

Volumn 55, Issue 4, 2004, Pages 495-502

  Winkel, Léon P F ^a   Van Den Hout, Johanna M P ^a   Kamphoven, Joep H J ^b   Disseldorp, Janus A M ^a   Remmerswaal, Maaike ^a   Arts, Willem F M ^a   Loonen, M Christa B ^a   Vulto, Arnold G ^b   Van Doorn, Pieter A ^b   De Jong, Gerard ^b   Hop, Wim ^b   Smit, G Peter A ^c   Shapira, Stuart K ^d   Boer, Marijke A ^b   Van Diggelen, Otto P ^b   Reuser, Arnold J J ^b   Van Der Ploeg, Ans T ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; RECOMBINANT HUMAN ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CHILD; DETERIORATION; DRUG DOSE REGIMEN; ENZYME REPLACEMENT; FATIGUE; FEMALE; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN TISSUE; LUNG FUNCTION; MALE; MAMMAL; MILK; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; ONSET AGE; PRIORITY JOURNAL; RABBIT; SKELETAL MUSCLE; SKIN MANIFESTATION; VENTILATOR; WALKING; WHEELCHAIR;

ADOLESCENT; ADULT; ALPHA-GLUCOSIDASES; ANIMALS; CHILD; FEMALE; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LINEAR MODELS; MALE; MUSCLE, SKELETAL; PILOT PROJECTS; RABBITS; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION;

EID: 12144287218     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20019     Document Type: Article

References (27)

1. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II; acid α-glucosidase (acid maltase) deficiency. In: The metabolic and molecular bases of inherited disease. 8th ed. Vol III. Scriver CR, Beaudet A, Sly WS, Valle D, eds. New York: McGraw-Hill, 2000:3389-3420.
2. Engel A, Hirschhorn R. Acid maltase deficiency. In: Myology. Vol 2. 2nd ed. Engel A, Franzini-Armstrong C, eds. New York: McGraw-Hill, 1994:1533-1553.
3. Van den Hout JMP, Hop W, Van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003; 112:332-340.
4. De Duve C. From cytosis to lysosomes. Fed Proc Am Soc Exp Biol 1964;23:1045-1049.
5. Van den Hout JMP, Reuser AJJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-398.
6. Van den Hout JMP, Kamphoven JHJ, Winkel LPF, et al. Long-term intravenous treatment of Pompe's disease with recombinant human alpha-glucosidase from milk. Pediatrics (in press).
7. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency. Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324:1464-1470.
8. Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749.
9. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
10. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344: 182-188.
11. Van der Ploeg AT, Bolhuis PA, Wolterman RA, et al. Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells. J Neurol 1988;235:392-396.
12. Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJJ, Oostra BA. Characterization of the human lysosomal α-glucosidase gene. Biochem J 1990;272:493-497.
13. Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet 1998;7:1815-1824.
14. Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 1999;8:2145-2153.
15. Van den Hout JMP, Reuser AJJ, de Klerk JBC, et al. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24: 266-274.
16. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
17. Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet 1978;30:132-143.
18. Winkel LPF, Kamphoven JHJ, Van den Hout JMP, et al. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve 2003;27:743-751.
19. Van der Ploeg RJO. Hand-held dynamometry. Thesis. Groningen: Rijksuniversiteit Groningen, Department of Neurology, 1992.
20. Beenakker EA, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. Neuromuscul Disord 2001;11:441-446.
21. Tindall B. Aids to the investigation of the peripheral nervous system. London, UK: Medical Research Council, 1986.
22. Russel D, Rosenbaum P, Gowland C, et al. Gross motor function measure manual. 2nd ed. Hamilton, Canada: McMaster University, 1993.
23. Haley SM, Coster WJ, Ludlow LH, et al. Pediatric evaluation of disability inventory. 1st ed. New England Medical Center Hospital, Boston: Pedi Research Group, 1992.
24. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001;91:534-551.
25. Reuser AJJ, Van den Hout JMP, Bijvoet AG, et al. Enzyme therapy for Pompe disease: from science to industrial enterprise. Eur J Pediatr 2002;161(suppl 1):S106-S111.
26. Dimond PF. Transgenic technology in the production of therapeutic proteins. Innovations Pharmaceutical Technol 2000; 92-97.
27. Monitor. Brave new world of pharmaceuticals. Economist 2002;365:5-6.